Pancreatic Cancer

June 24th 2025

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic pancreatic ductal adenocarcinoma.

June 23rd 2025

Tripp Razor highlights the disproportionately high pancreatic cancer risk among Black Americans and the systemic disparities they face in access to care.

June 18th 2025

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

June 13th 2025

I was told I wouldn’t live to see my daughters’ weddings — but 12 years later, I’ve been there for two, and I’m holding out hope for the third.